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Immunization with virus-like particles 
conjugated to CIDRα1 domain of Plasmodium 
falciparum erythrocyte membrane protein 1 
induces inhibitory antibodies
Charlotte Harmsen1,2, Louise Turner1,2, Susan Thrane1,2, Adam F. Sander1,2, Thor G. Theander1,2 
and Thomas Lavstsen1,2* 
Abstract 
Background: During the erythrocytic cycle, Plasmodium falciparum malaria parasites express P. falciparum Eryth-
rocyte Membrane Protein 1 (PfEMP1) that anchor the infected erythrocytes (IE) to the vascular lining of the host. 
The CIDRα1 domain of PfEMP1 is responsible for binding host endothelial protein C receptor (EPCR), and increasing 
evidence support that this interaction triggers severe malaria, accounting for the majority of malaria-related deaths. 
In high transmission regions, children develop immunity to severe malaria after the first few infections. This immunity 
is believed to be mediated by antibodies targeting and inhibiting PfEMP1, causing infected erythrocytes to circulate 
and be cleared in the spleen. The development of immunity to malaria coincides with acquisition of broad antibody 
reactivity across the CIDRα1 protein family. Altogether, this identifies CIDRα1 as an important vaccine target. However, 
the antigenic diversity of the CIDRα1 domain family is a challenge for vaccine development.
Methods: Immune responses in mice vaccinated with Virus-Like Particles (VLP) presenting CIDRα1 antigens were 
investigated. Antibody reactivity was tested to a panel of recombinant CIDRα1 domains, and the antibodies ability to 
inhibit EPCR binding by the recombinant CIDRα1 domains was tested in Luminex-based multiplex assays.
Results: VLP-presented CIDRα1.4 antigens induced a rapid and strong IgG response capable of inhibiting EPCR-bind-
ing of multiple CIDRα1 domains mainly within the group A CIDRα1.4–7 subgroups.
Conclusions: The study observations mirror those from previous CIDRα1 vaccine studies using other vaccine con-
structs and platforms. This suggests that broad CIDRα1 antibody reactivity may be achieved through vaccination with 
a limited number of CIDRα1 variants. In addition, this study suggest that this may be achieved through vaccination 
with a human compatible VLP vaccine platform.
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Background
Malaria caused by Plasmodium falciparum is still a 
leading disease accounting for considerable under-five 
mortality in sub-Saharan Africa. In areas of moderate 
to high transmission intensity, severe life-threatening 
malaria mainly affects infants and toddlers, as immu-
nity against severe disease is acquired at a young age 
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after a few malaria episodes [1–3]. Young children who 
have acquired immunity to severe infections are still sus-
ceptible to less severe malaria episodes and immunity 
against these gradually forms during childhood [4]. This 
development of immunity can be explained by a gradual 
acquisition of IgG against variable polymorphic proteins 
expressed on the surface of infected erythrocytes [5–9]. 
Members of the P. falciparum Erythrocyte Membrane 
Protein 1 (PfEMP1) family are considered main targets 
of this immunity. These proteins are anchored in the 
erythrocyte membrane exposing their large N-terminal 
to engage with receptors on endothelial cells (reviewed in 
[10]). This permits an effective sequestration of infected 
erythrocytes to the endothelial lining and allows these 
cells to escape blood flow and splenic filtration. On the 
erythrocyte surface, PfEMP1 is accessible to antibodies 
functionally inhibiting the binding between the infected 
erythrocyte and the endothelium. These antibodies are 
thought to be important mediators of immunity [11–14].
Each parasite genome contains 50–60 PfEMP1en-
coding var genes, which differ in sequence within and 
between parasites, and of which each parasite will express 
only one during the erythrocytic cycle [15]. Despite their 
extensive sequence diversity, the distribution of different 
PfEMP1 types is similar in all parasites [16]. PfEMP1s are 
composed of two to nine Duffy Binding-like (DBL) and 
cysteine-rich interdomain region (CIDR) domains, and in 
most PfEMP1 the second domain from the N-terminus 
is a CIDR domain [16]. These domains have diversified 
to confer binding to either endothelial protein C recep-
tor (EPCR) (CIDRα1 domains) [17], CD36 (CIDRα2–6 
domains), or unknown receptors (CIDRβ/γ/δ domains). 
These mutually exclusive binding phenotypes are main-
tained by chromosomal separation of the encoding 
genes, with so-called group B and C var genes encod-
ing CD36-binding PfEMP1 and group A genes encoding 
EPCR-binding PfEMP1 and CIDRβ/γ/δ-domain PfEMP1. 
In addition, most parasites carry one to three variants 
of the so-called DC8 group B/A chimeric var genes also 
encoding EPCR-binding PfEMP1 [18].
Numerous studies have linked EPCR-binding parasites, 
or parasites expressing CIDRα1-PfEMP1, with develop-
ment of severe malaria in including when it is presenting 
as cerebral malaria and severe anemia. No other PfEMP1 
domain is consistently associated with severe malaria 
pathology [19–21]. However, CIDRα1-PfEMP1 are large 
multi-domain molecules, and it is likely that endothelial 
receptor-interactions of some accompanying domains act 
in concert with EPCR-binding to promote parasite sur-
vival. For example, current evidence suggests that sup-
plementary binding to ICAM1 or HABP1 is associated 
with EPCR binding by group A [21, 22] and B/A PfEMP1 
[23], respectively. PfEMP1 binding to EPCR abrogates 
EPCR-mediated conversion of protein C to activated pro-
tein C, which promotes a pro-inflammatory state of the 
endothelium prone to thrombin-induced expression of 
endothelial cell adhesion molecules including the Inter-
cellular Adhesion Molecule 1 (ICAM1) [24, 25].
All CIDRα1 domains adopt a similar fold in order to 
bind EPCR with high affinity [26]. The EPCR binding 
mechanism of the CIDRα1 domain mimics that of acti-
vated protein C to EPCR, indicating that an evolutionary 
stalemate has been reached, in which neither the parasite 
or human protein can mutate its basic structure with-
out compromising its vital function. However, immune 
selection pressure has imposed extensive sequence 
diversity across surface exposed amino acids on the 
CIDRα1 domain, albeit limited to variation maintain-
ing structure and the physio-chemical properties of the 
amino acids directly interacting with EPCR. As a result, 
EPCR-binding CIDRα1 sequence variants distribute into 
six subgroups, CIDRα1.1 and CIDRα1.4–1.8, of which 
CIDRα1.1 and 1.8 are found in group B/A PfEMP1 and 
the rest among group A PfEMP1. The EPCR-binding 
site is essentially comprised of a ~ 25 amino acid kinked 
alpha-helix structure protruding from a core triple 
helix structure [26]. Across the 19  kDa minimal bind-
ing domain of CIDRα1, sequences are pairwise 40–100% 
identical. The average sequence identity within CIDRα1 
subgroups (e.g. 1.1) is 69–72%, but short amino acid 
stretches of high similarity are shared across members of 
different subtypes [26].
Experimental immunization of mice and rats with sin-
gle or multiple soluble CIDRα1 proteins, or adenovirus 
inducing in  vivo secretion of CIDRα1 protein, readily 
elicit EPCR binding-inhibitory IgG to cognate antigens, 
as well as to CIDRα1 variants of the same CIDRα1 sub-
type as the used immunogen [27, 28]. The most het-
erogeneous of CIDRα1 subtypes is the CIDRα1.4 and 
CIDRα1.7 domains, to which it appears to be particularly 
difficult to elicit cross-ractive antibodies. Vaccines pre-
senting antigens on Virus-Like Particles (VLP) have been 
shown to induce high tittered, long lasting functional 
IgG responses in humans [29, 30] and can drive immune 
responses even to weakly immunogenic or self-antgens 
[31, 32]. We, and others, have recently developed a tech-
nique that allows effective coupling of complex pro-
teins to pre-formed VLP and demonstrated that the IgG 
response to the proteins coupled is potent, functional, 
and durable even with self-antigens [31, 33, 34]. Here, 
VLP-CIDRα1.4 vaccines adjuvanted with aluminum 
hydroxide elicited stronger immune responses than a 
similar soluble CIDRα1 vaccine in Freund’s incomplete 
adjuvant, and antibodies reactive and functionally inhibi-
tory across group A CIDRα1 variants was elicited from 
immunization with a single CIDRα1 antigen variant.
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Methods
Recombinant protein and VLP production
Proteins were produced in baculovirus-infected High 
Five cells as previously described [35]. CIDRα1 pro-
teins derived from the HB3var03 PfEMP1 sequence 
were genetically fused with the SpyCatcher [36] protein 
sequence at the N-terminal or C-terminal and a Strep-tag 
II sequence in the opposite terminal (total size 32 kDa): 
catCIDRα1.4 (SpyCatcher-CIDRα1.4-Strep-tag II), and 
CIDRα1.4cat (Strep-tag II-CIDRα1.4-SpyCatcher).
SpyT-VLPs formed by 180 capsid units of the Aci-
netobacter bacteriophage AP205 and displaying one 
SpyTag per capsid unit, were produced as previously 
described [31]. In brief, the SpyTag sequence (AHIVM-
VDAYKPTK) was fused to the N-terminus of each capsid 
using a flexible linker (GSGTA GGG SGS). The construct 
was expressed in E. coli One Shot BL21 StarTM (DE3) 
cells (Thermo Scientific) and purified by ultracentrifu-
gation using an OptiprepTM density gradient (Sigma). 
Naked VLP formed from AP205 capsids with no SpyTag 
were produced using the same method.
Assembled SpyTagged VLP and soluble SpyCatcher-
fused CIDRα1.4 antigen were mixed at a 1:1 molar ratio 
(VLP capsid per antigen) and incubated over night at 
4  ℃, forming a ~ 48  kDa band on SDS-PAGE under 
reducing conditions (Fig. 1). Uncoupled antigen was not 
removed from the vaccine before administration.
Dynamic light scattering (DLS) was performed as pre-
viously described [31]. Briefly, the distribution of VLP 
particle sizes was acquired at 658  nm, 25  ℃ (WYATT 
Technology, DynaPro NanoStar). Each VLP prepara-
tion was measured twice with 20 runs and the estimated 
diameter of the main particle population and the percent 
polydispersity (%Pd) was calculated.
Mice and immunizations
Female BALB/c mice (Taconic, Denmark), 7–8 weeks old, 
were immunized by intramuscular injection three times, 
at 3-week intervals. The mice were given 5 µg CIDRα1.4 
antigen per mouse per immunization, administered 
as either bound to 2.5  µg SpyTag-VLP or without any 
VLP. In total 16 mice were distributed between the four 
groups: VLP-catCIDRα1.4 (five mice), CIDRα1.4cat-VLP 
(five mice), catCIDRα1.4 (three mice), and CIDRα1.4cat 
(three mice). VLP-coupled antigen was administered 
with Alhydrogel (2%) (Brenntag) added to the vaccine 
formulation 1 h prior to immunization, whereas antigens 
with no VLP was administered with Freund’s incomplete 
adjuvant (1:1, W/W). Serum was collected 2 weeks after 
each immunization. Total IgG was purified using Gam-
maBind Plus Sepharose (BD Biosciences) according to 
the manufacturer’s protocol.
ELISA analyses
Serum levels of antigen specific IgG were measured as 
previously described [31]. In brief, plates were coated 
with 5  µg/mL 30  kDa HIS-tagged HB3var03 CIDRα1.4 
protein [28]. The wells were blocked with 1% BSA buffer. 
ba
Fig. 1 Characterization of VLP-antigen conjugated vaccines. a Dynamic light scattering (DLS) showing SpyT-VLP (blue) with an average size of 37 
nm (12.18% polydispersity, Pd). After coupling VLP to catCIDRα1.4 (brown) or CIDRα1.4cat (green) the size increases to 56 nm (12.19%Pd) and 88 nm 
(27.83 %Pd), respectively. b SDS-gel loaded with catCIDRα1.4 or CIDRα1.4cat antigens (32kDa) mixed with SpyT-VLP (16kDa) or naked VLP (8kDa): 1. 
SpyT-VLP; 2. Naked VLP + catCIDRα1.4; 3. SpyT-VLP + catCIDRα1.4; 4. Naked VLP + CIDRα1.4cat; 5. SpyT-VLP + CIDRα1.4cat
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Mouse serum was added in a series of three-fold dilu-
tions starting from 1:50. Secondary antibody (HRP-con-
jugated anti mouse IgG (Life Technologies, Denmark)) 
was diluted 1:3000 and color reactions were developed 
for 7 min by adding o-phenylenediamine substrate.
IgG reactivity and EPCR‑binding inhibition of diverse 
CIDRα1 domains
IgG reactivity to a panel of 43 recombinant CIDRα1 
domains coupled to Luminex microspheres was meas-
ured as in [37]. In short, serum was diluted 1:80, and IgG 
reactivity was detected using secondary phycoerythrin 
(PE)-conjugated antibody diluted to 1:3000. For assessing 
EPCR-binding inhibition, purified IgG from each mouse 
within a vaccine group was pooled and incubated at 
0.25  mg/mL IgG with the CIDRα1-conjugated Luminex 
microspheres for 30  min at room temperature. After 
washing with standard Luminex buffers, microspheres 
were incubated with 4  µg/mL biotinylated recombinant 
EPCR for 30  min at room temperature. EPCR-binding 
was detected using PE-conjugated streptavidin. The 
CIDRα1 protein variants with low binding to EPCR when 
coupled to microspheres were excluded from the inhibi-
tion study leaving 34 variants tested.
Data analysis
Data were analysed using Microsoft Excel and STATA 
(StataCorp). Non-parametric statistical tests was used as 
indicated in the result section. IgG titers were calculated 
as area under curve using STATA14 using the pkexamine 
command using dilution as time parameter over 11 dilu-
tion steps, ELISA OD as concentration parameter and 
the trapezoidal rule.
Protein sequences
catCIDRα1.4 (SpyC‑HB3var03‑Strep‑Tag II) (linkers in lower 
case)
GAMVDTLSGLSSEQGQSGDMTIEEDSATHIKFSKRD 
EDGKELAGATMELRDSSGKTISTWISDGQVKDFY 
LYPGKYTFVETAAPDGYEVATAITFTVNEQGQVT 
VNGKATKGDAHIggsKITSFDEFFDF WVRKLLID 
TIKWETELT YCINN TDV TD CNKCNKNC VCFD 
KW V KQK E DEW TN IMK L F TN K H DI PK KYYL N 
INDLFDSFFFQVIYKFNEGEAKWNELKENLKKQIASS 
KANNGTKDSEAAIKVLFNHIKEIATICKDNNTNEGrtg 
WSHPQFEK.
CIDRα1.4cat (Strep‑tag‑II‑HB3var03‑SpyC) (linkers in lower 
case)
WSHPQFEKrtgKITSFDEFFDF WVRKLLIDTIKW 
ETELTYCINNTDVTDCNKCNKNCVCFDKWVKQKE 
DEWTNIMKLFTNKHDIPKKYYLNINDLFDSFFFQVIY 
KFNEGEAKWNELKENLKKQIASSKANNGTKD-
SEAAIKVLFNHIKEIATICKDNNTNEGggsGAMV 
DTLSGLSSEQGQSGDMTIEEDSATHIKFSKRDEDGK 
ELAGATMELRDSSGKTISTWISDGQVKDFYLYPGK 
YTFVETAAPDGYEVATAITFTVNEQGQVTVNGKAT 
KGDAHI.
Results
Production VLP‑based CIDRα1 vaccines
Two recombinant CIDRα1 proteins both derived from 
the HB3var03 PfEMP1 CIDRα1.4 sequence were pro-
duced with a SpyCatcher protein sequence in either 
the N-terminal or the C-terminal (catCIDRα1.4 and 
CIDRα1.4cat, respectively) (Fig.  1). The recombinant 
proteins were coupled to bacteriophage AP205 SpyTag-
VLP particles. These particles form spontaneously from 
180 AP205 capsid proteins, each with a genetically fused 
SpyTag in the N-terminus. By mixing a recombinant 
SpyCatcher-fused CIDRα1.4 protein with the pre-formed 
VLP, the SpyTags and SpyCatchers formed covalent 
bonds, resulting in VLP coupled with CIDRα1.4 antigen 
(Fig. 1).
Analysis of the IgG reactivity to the CIDRα1 domain used 
as immunogen
The two VLP based CIDRα1.4 vaccines and two vac-
cines containing the corresponding soluble proteins 
were administered by intramuscular injection to BALB/c 
mice over three immunizations with 3-week inter-
vals. Two groups of five mice received catCIDRα1.4 or 
CIDRα1.4cat displayed on VLP in aluminum hydroxide 
and two groups of three mice received catCIDRα1.4 or 
CIDRα1.4cat without VLP but with Freund’s incomplete 
adjuvant.
Serum collected 2  weeks after each of the three 
immunizations was assessed for induction of IgG bind-
ing to cognate HB3var03 CIDRα1.4 domains (without 
the SpyCatcher tag of the immunogens) in ELISA. The 
CIDRα1.4-VLP vaccines in aluminum hydroxide induced 
a faster and stronger IgG response against the cognate 
HB3var03 CIDRα1.4 antigen than the vaccines with solu-
ble antigen in Freund’s incomplete adjuvant (Fig. 2). The 
effect was most pronounced after the first immunization 
(Fig. 2, 1st bleed).
Analysis of IgG reactivity to sequence diverse CIDRα1 
domain variants
Next, the reactivity of serum IgG to different CIDRα1 
protein variants (N = 43), and the ability to inhibit bind-
ing between 34 of these variants and EPCR with total 
purified IgG, was tested using a Luminex based multi-
plex-system. Luminex microspheres coupled with indi-
vidual CIDRα1 domains were mixed and used in assays 
measuring the amount of IgG binding each antigen (IgG 
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Area under the curve catCIDRα1 CIDRα1cat P (On vs  No VLP)
mean ±SD mean ±SD catCIDRα1 CIDRα1cat
1st bleed On VLP
7.5 1.5 2.9 0.5
0.03 0.07
No VLP 2.3 1.4 1.9 0.8
2nd bleed On VLP
8.3 1.1 8.5 0.7
0.003 0.009
No VLP 2.9 2.5 4.5 2.4
3rd bleed On VLP
8.7 1.5 8.0 0.8
0.002 0.01
No VLP 3.5 1.9 5.2 1.6
Page 6 of 11Harmsen et al. Malar J          (2020) 19:132 
level, Mean Fluorescence Intensity (MFI)) or the abil-
ity of EPCR to bind CIDRα1 on the microsphere in the 
presence of IgG (inhibition of EPCR-binding, Inhibition 
(%)). Figure  3 shows the antibody levels measured in 
serum from individual mice, and the inhibitory activity 
of purified total IgG pooled from animals receiving the 
same vaccine (both with serum collected 2  weeks after 
the third immunization). This analysis confirmed that 
the VLP vaccines induced higher levels of IgG to the 
cognate immunogen (HB3var03) than the vaccines with 
soluble antigen in Freund’s incomplete adjuvant (Fig. 3a, 
P = 0.03 and P = 0.05 for catCIDRα1.4 and CIDRα1.4cat, 
respectively; Wilcoxon rank-sum test). Furthermore, all 
vaccines induced IgG with high capacity to inhibit EPCR-
binding of the cognate CIDRα1 immunogen (Fig. 3b).
When assessing the serum reactivity and EPCR-bind-
ing inhibitory potential of purified IgG to the panel of 
CIDRα1 domains not included in the vaccine (Fig.  3c, 
d), reactivity to and inhibition of specific variants varied 
considerably. However, there was no overall difference in 
these parameters between the VLP coupled and the solu-
ble vaccines. When plotting the inhibition data for each 
c d
a b
Fig. 3 Antibody reactivity and EPCR-binding inhibition in Luminex. a Anti-HB3var03 CIDRα1.4 IgG levels in serum. b EPCR-binding inhibition of 
pooled, purified IgG in  %. c Serum-IgG levels to 42 CIDRα1 protein variants not including the immunogen variant HB3var03 measured in 3–5 
mice. d EPCR-binding inhibition of 33 EPCR-binding CIDRα1 protein variants (also excluding HB3var03). All for mice immunized with catCIDRα1.4 
or CIDRα1.4cat on VLP or as soluble antigen in Freund’s incomplete adjuvant. Box plots showing median reactivity with 25th and 75th percentiles, 
upper and lower adjacent values and outliers. *Indicate statistically significant difference, P = 0.03 and P = 0.05 for catCIDRα1.4 and CIDRα1.4cat, 
respectively using Wilcoxon rank-sum test
(See figure on previous page.)
Fig. 2 Anti-CIDRα1.4 IgG. ELISA titers elicited in mice vaccinated with catCIDRα1.4 or CIDRα1.4cat. Each line represents the titration of serum from 
a mouse. Black lines indicate serum from mice immunized with CIDRα1.4-VLP in aluminum hydroxide. Red lines indicate mice immunized with 
soluble CIDRα1.4 in Freund’s incomplete adjuvant. Table shows titers calculated as area under the curve for each vaccine group (mean ± standard 
deviation), P values from t-tests
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specific CIDRα1 domain variant assayed (Fig. 4), inhibi-
tion was consistently observed for some domains. Over-
all, the CIDRα1 variants to which inhibitory antibodies 
were elicited were common to the four vaccines, albeit 
inhibition was somewhat more pronounced for IgG elic-
ited by the catCIDRα1.4 antigens. If 40% inhibition was 
applied as a cutoff the VLP-catCIDRα1.4 vaccine induced 
IgG, inhibitingsix of 20 tested group A CIDRα1 variants 
(CIDRα1.4–7) and none of 13 CIDRα1.1/1.8 variants 
tested from the group B/A PfEMP1 (a.k.a. DC8 PfEMP1). 
IgG elicited by the soluble catCIDRα1.4 vaccine inhibited 
seven of 20 heterologous CIDRα1 variants from group 
A, and two of 13 CIDRα1.1/1.8 variants. Interestingly, in 
particular the binding of CIDRα1.7 domains, which are 
closest related to CIDRα1.4 used as immunogen, were 
inhibited. Raw data given in Additional File 1.
There was a clear but not absolute correlation between 
IgG level to and the IgG binding inhibition of the sin-
gle CIDRα1 domains (Ks = 0.67, P = 0.0001, Spearman’s 
rank-order correlation) (Fig.  5). For many domains, 
however, there was a considerable antibody recognition 
(MFI > 1000) without high inhibitory capacity. A particu-
lar high reactivity without strong inhibition was seen for 
two specific CIDRα1.4 variants (CIDRα1.4 1983–5 and 
CIDRα1.4_DD2var32). This may indicate that elicited 
antibodies targeted shared non-inhibitory epitopes of the 
domains or that the affinity of the elicited antibodies was 
insufficient to compete with EPCR.
Figure  6 shows the sequence relation between the 
studied CIDRα1 variants. Overall sequence similarity 
between immunogen and antigen was not clearly associ-
ated with antigen inhibition, albeit that the most similar 
domain, sharing 88% amino acids with the immunogen 
Fig. 4 Inhibition of EPCR-binding of specific CIDRα1 domain variants. EPCR-binding inhibition (%) of 34 recombinant CIDRα1 domains by 
purified IgG pooled from mice immunized with VLP-catCIDRα1.4, catCIDRα1.4, CIDRα1.4cat-VLP or CIDRα1.4cat. Each bar represents one specific 
recombinant CIDRα1 domain variant annotated according to its domain subtype. Arrows indicate the HB3var03 variant used as immunogen. Order 
of CIDRα1 protein variants tested is shown as listed in Fig. 6a
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variant, was the strongest inhibited. No distinct amino 
acid sequence trait shared between inhibited CIDRα1 
variants could be identified from sequence alignments 
(from visual inspection and with SigniSite, http://www.
cbs.dtu.dk/servi ces/Signi Site/). However, overall it was 
mainly CIDRα1 variants within group A, and in particu-
lar the CIDRα1.7 variants, that were inhibited.
Discussion
Increasing evidence support that the interaction between 
the CIDRα1 domains of PfEMP1 and EPCR is key to the 
development of severe P. falciparum malaria [38]. Parasites 
causing severe malaria mainly express PfEMP1 binding 
EPCR and increasing proportions of EPCR-binding para-
sites appears to be associated with increase with severity of 
symptoms. No other PfEMP1 domain or trait shows this 
association [20, 21, 39–44], despite all PfEMP1 carrying addi-
tional domains capable of interacting with host receptors. 
This strong association may be tied to the observation that 
CIDRα1 binding to EPCR disrupts EPCR function, trigger-
ing endothelial inflammation and vascular leakage, charac-
teristic for the pathology of severe malaria [45]. Children in 
malaria endemic areas develop immunity to severe malaria 
after relatively few infections coinciding with the acquisition 
of antibodies to CIDRα1 [9, 46]. For these reasons, CIDRα1 
is considered an important target for vaccines protecting 
against clinical and particularly severe malaria [47].
However, the challenge to vaccine development is the 
antigenic diversity of the CIDRα1 domains. Based on 
amino acid sequence, the domains can be divided into six 
subclasses (1.1, and 1.4–1.8), each of which contain many 
different sequence variants. Despite the considerable 
amino acid variation, the protein structure and molecular 
basis of the interaction with EPCR is maintained across 
CIDRα1 domains [26]. Immunity to severe malaria is 
acquired relatively fast, which suggests that natural infec-
tion can induce IgG, targeting a relatively broad panel of 
CIDRα1 types. This notion is supported by the fact that 
IgG purified from malaria-exposed children and by affin-
ity for a single CIDRα1.1 variant, can inhibit the EPCR-
binding of distant CIDRα1.4 variants and vice versa 
[26]. The complexity of these antibody pools remains 
unknown. However, as short 63-mer peptides spanning 
the EPCR binding site was used for affinity purification in 
these studies, the data suggest that inhibitory antibodies 
interact with similar epitopes at or near the EPCR-bind-
ing site of different CIDRα1 variants [26].
In the present study, CIDRα1.4 immunization read-
ily produced antibodies inhibiting the EPCR-binding of 
the CIDRα1.4 variant present in the vaccines as well as 
other CIDRα1 variants typically within the same sub-
group as the immunogen. This was also seen in previ-
ous studies [27, 28], where animals were vaccinated with 
soluble recombinant CIDRα1 domains or live attenuated 
adenovirus inducing in  vivo CIDRα1 protein secretion. 
In these studies, induction of cross-reactive antibodies 
was most clearly demonstrated by vaccination using two 
CIDRα1.1 domains resulting in antibodies reactive to 11 
of 14 group B/A (CIDRα1.1 and CIDRα1.8) antigen vari-
ants [27]. The group B/A PfEMP1 are encoded by a set of 
chimeric var genes originating from group A and B var 
gene recombination events 5′ to the CIDRα1 sequence. 
Due to the opposite directions of transcription of group 
A vs. B and B/A var genes, these var gene subfamilies 
are likely to have evolved separately. Within group A 
PfEMP1, CIDRα1 domains have diverged into groups, 
with CIDRα1.4 and 1.7 variants being the closest related. 
Within subgroups CIDRα1 domains are typically 65–75% 
pairwise identical [16]. Between group A and B/A, 
CIDRα1 variants are on average 46% pairwise identical. 
The data presented here, indicate that immunization 
with a group A CIDRα1 mainly elicited cross-binding 
inhibitory antibodies against other group A CIDRα1 vari-
ants. This suggests that group B/A and group A CIDRα1 
domains, to a certain extent comprise two separate sero-
groups. It was not possible from the present data to iden-
tify shared specific epitopes responsible for recognition 
and inhibition across variants.
Vaccines based on VLP-conjugated antigens are very 
effective in inducing long-lived functional antibodies. 
The best examples are the HPV vaccines, which after 
two immunizations elicit IgG maintained at stable levels 
Fig. 5 Correlation between anti-CIDRα1 IgG levels and EPCR-binding 
inhibitory capacity of CIDRα1 domains in pooled IgG purified from 
mice immunized with VLP-catCIDRα1.4. Each dot represents one 
EPCR-binding CIDRα1 domain and colors represent each of the four 
immunization schemes (34 domains × 4 immunization groups): 
VLP-catCIDRα1.4 (red), catCIDRα1.4 (orange), CIDRα1.4cat-VLP 
(blue), and CIDRα1.4cat (green). The immunogen CIDRα1.4 variant 
is outlined. The box includes indicates data from three CIDRα1.4_
DD2var32 and one CIDRα1.4_1983-5 domain
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for decades [29, 30]. Recently, methods that enable cou-
pling of complex antigens to pre-formed VLP have been 
developed, employing the SpyTag/SpyCatcher conjuga-
tion system [31, 33, 34]. Employed in mice, these VLP 
vaccines have induced high and stable IgG levels against 
microbial antigens, including malaria antigens [48–51]. 
The VLP system secures a dense presentation of the vac-
cine antigen keeping an identical orientation on a rigid 
virus particle. The dense and repetitive presentation 
of antigens in their native conformation can override B 
cell tolerance and thus may alter not only the strength 
and longlivity of the response, but potentially also the 
epitopes targeted. In the case of CIDRα1 antigens, VLP 
presentain could therefore potentially alter the breadth 
of the immuneresponse to a broader reactivity across the 
protein family.
Here, the VLP-conjugated CIDRα1.4 vaccines induced 
an IgG response, which was higher and more rapid than 
the corresponding soluble vaccines formulated in Fre-
und’s incomplete adjuvant. The EPCR-binding inhibi-
tory effect across diverse CIDRα1 domains was similar 
for antibodies elicited by the VLP-based and the soluble 
CIDRα1.4 vaccines. This is important as Freund’s incom-
plete adjuvant cannot be used in humans, whereas the 
VLP platform is expected to be approved for human use 
and is likely be able to induce high tittered long-lasting 
immune responses in humans [52].
ba
GROUP A
Protein %ID
CIDRa1.1_IT4var20 46
CIDRa1.1_PFD0020c 41
CIDRa1.1_2110-3 43
CIDRa1.1_IGHvar19 50
CIDRa1.1_IT4var06 40
CIDRa1.1_RAJ116var08 44
CIDRa1.1_IT4var19 41
CIDRa1.4_DD2var32 63
CIDRa1.4_PF11_0521 60
CIDRa1.4_IT4var07 88
CIDRa1.4_GA24 66
CIDRa1.4_1974-5 70
CIDRa1.4_1994-2 56
CIDRa1.4_1983-5 64
CIDRa1.4_HB3var03 100
CIDRa1.5a_1965-2 50
CIDRa1.5a_GA13 47
CIDRa1.5a_GA14 49
CIDRa1.6a_PFD1235w 51
CIDRa1.6b_GA19 64
CIDRa1.6a_HB3var02 53
CIDRa1.6b_IT4var18 57
CIDRa1.6b_GA18 65
CIDRa1.7_DD2var49 56
CIDRa1.7_IT4var22 58
CIDRa1.7_1965-8 59
CIDRa1.7_1983-7 56
CIDRa1.7_2083-1 56
CIDRa1.8a_MAL6P1.316 47
CIDRa1.8b_GA29 41
CIDRa1.8b_1702-3 42
CIDRa1.8a_GA26 47
CIDRa1.8a 1965-3 47
CIDRa1.8b_2053-3 52
Fig. 6 Sequence analysis of CIDRα1 domains. a Pairwise sequence similarity (19 kDa sequences) of the assayed CIDRα1 domains to HB3var03 
CIDRα1.4. Blue (immunogen variant) and red asterisks (*) mark CIDRα1 domain variants inhibited > 40%. b Maximum likelihood tree (key bootstrap 
[N = 50] values are indicated on branches) of 885 CIDRα1 sequences (30 kDa) (generated in [26]). The 34 CIDRα1 variants tested for EPCR-binding 
inhibition (marked with boxes) are red if inhibited > 40% by total purified IgG from animals immunized with VLP-catCIDRα1.4 or for the cognate 
immunogen, blue. CIDRα1 variants not inhibited are green
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Immunizations with CIDRα1.4 fused to SpyCatcher 
N-terminally appeared to induce somewhat higher lev-
els of inhibition than CIDRα1.4 with a SpyCatcher fused 
C-terminal. The C-terminal of CIDRα1 is positioned near 
the EPCR-binding site [26], and it is possible that a C-ter-
minal fusion of a SpyCatcher adversely affected induction 
of antibodies to epitopes near or at the EPCR binding site. 
Overall, the VLP-presentation of CIDRα1 did not improve 
the reactivity across the CIDRα1 family, and it is likely that 
only a fraction of the elicited antibodies are functional. 
Additional studies testing inhibition of homologous native 
CIDRα1.4 PfEMP1 may further elucidate the relevance of 
the differences seen in EPCR binding inhibition by IgG 
elicited by the antigens presented on or off the VLP.
Conclusions
This study showed that immunization with VLP-conju-
gated CIDRα1.4 antigens induced a rapid and strong IgG 
response capable of inhibiting EPCR-binding of CIDRα1 
proteins belonging to different CIDRα1 subgroups. Data 
from this and previous studies suggest that vaccination 
with a limited combination of antigens can induce an 
antibody response covering most EPCR-binding CIDRα1 
variants. Future studies including in  vitro studies using 
natively expressed PfEMP1, are needed to clarify how 
many variants are required to obtain broad coverage 
across the CIDRα1 protein family and if such combina-
tions can be achieved through display of multiple anti-
gens on vaccine platforms, such as VLP vaccines, most 
likely to induce potent immune responses in humans.
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